樂普生物-B(02157.HK)以1.25億元人幣出售杭州皓陽15%股權
樂普生物-B(02157.HK)公布,向康哲藥業(00867.HK)出售杭州皓陽生物技術15%股權,代價1.25億元人民幣(下同)。
公司估計出售事項錄得收益約6,250萬元,即出售事項所得款項淨額與6月30日股份賬面值之間的差額。出售事項所得款項淨額將用作一般營運資金。
杭州皓陽主要為生物科技公司提供技術開發服務,公司認為出售事項能夠實現財務投資價值。交易完成後,持股量由20.68%減少至5.68%,不再為聯營公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.